FDA
-
-
-
-
-
-
-
Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
-
-
-
-
-
-
-
Momenta Phama (MNTA) Announces Year-End 2019 Update and 2020 Outlook
-
-
-
-
-
-
-
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation
-
-
-
-
-
-
-
Momenta Phama (MNTA) Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in Human Term Placenta
-
-
-
-
-
-
-
Momenta Pharmaceuticals to Webcast Presentation at theĀ 37th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Momenta Phama (MNTA) Announces Revised US Regulatory Strategy for M923
-
-
-
-
-
-
-
Momenta Pharmaceuticals Announces Date of Third Quarter 2018 Financial Results Conference Call and Webcast
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

